Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

The Use of Anti-IgE Therapy Beyond Allergic Asthma

“…38 A retrospective analysis of 4 adult patients with stage IV ABPA (corticosteroid-dependent) treated with omalizumab for 12 months found that it was steroid sparing and reduced inflammatory markers and symptom scores. 39 …”

Omalizumab Treatment for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis

“…The patient experienced a severe relapse with FEV1 decline and remained steroid dependent over the treatment period. 7 The aim of this report is to describe our experience with omalizumab treatment in patients with CF and ABPA.…”

Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature

“…A self placebo-controlled randomized trial involved 13 volunteers was recently finished in Australia and the authors found that clinical improvement was accompanied by decreased basophil reactivity to A. fumigatus and FcεR1 and surface-bound IgE level [49]. Novartis conducted a double-blind study evaluating the safety and efficacy of Omalizumab for the treatment of ABPA in patients with CF aged 12 years and older from November, 2008 (NCT00787917), but this study was terminated on July 11, 2011 due to adverse events [54]. More over 38 cases of ABPA treated with Omalizumab were mentioned in previous citations without any data available, so those cases were excluded from our analyses.…”